SULF1 Inhibits Tumor Growth and Potentiates the Effects of Histone Deacetylase Inhibitors in Hepatocellular Carcinoma

Gastroenterology

Volumn 130, Issue 7, 2006, Pages 2130-2144

  Lai, Jin Ping ^a   Yu, Chunrong ^b   Moser, Catherine D ^a   Aderca, Ileana ^a   Han, Tao ^a   Garvey, Thomas D ^a   Murphy, Linda M ^b   Garrity Park, Megan M ^b   Shridhar, Viji ^b   Adjei, Alex A ^b   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SULFATASE;

ACETYLATION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; METASTASIS; MOUSE; NONHUMAN; NUCLEOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION; XENOGRAFT;

EID: 33744541875     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.02.056     Document Type: Article

References (38)

1. Roberts L.R., and Gores G.J. Hepatocellular carcinoma. molecular pathways and new therapeutic targets. Semin Liver Dis 25 (2005) 212-225
2. Lai J.P., Chien J.R., Moser D.R., Staub J.K., Aderca I., Montoya D.P., Matthews T.A., Nagorney D.M., Cunningham J.M., Smith D.I., Greene E.L., Shridhar V., and Roberts L.R. hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126 (2004) 231-248
3. Lai J., Chien J., Staub J., Avula R., Greene E.L., Matthews T.A., Smith D.I., Kaufmann S.H., Roberts L.R., and Shridhar V. Loss of HSulf-1 up-regulates heparin-binding growth factor signaling in cancer. J Biol Chem 278 (2003) 23107-23117
4. Lai J.P., Chien J., Strome S.E., Staub J., Montoya D.P., Greene E.L., Smith D.I., Roberts L.R., and Shridhar V. HSulf-1 modulates HGF-mediated tumor cell invasion and signaling in head and neck squamous carcinoma. Oncogene 23 (2004) 1439-1447
5. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer. causes and therapies. Nat Rev Cancer 1 (2001) 194-202
6. Zhu W.G., and Otterson G.A. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3 (2003) 187-199
7. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., and Scher H. Phase I clinical trial of histone deacetylase inhibitor. suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9 (2003) 3578-3588
8. Abramoff M.D., Magelhaes P.J., and Ram S.J. Image processing with ImageJ. Biophotonics International 11 (2004) 36-42
9. McManus K.J., and Hendzel M.J. Quantitative analysis of CBP- and P300-induced histone acetylations in vivo using native chromatin. Mol Cell Biol 23 (2003) 7611-7627
10. Guidez F., Howell L., Isalan M., Cebrat M., Alani R.M., Ivins S., Hormaeche I., McConnell M.J., Pierce S., Cole P.A., Licht J., and Zelent A. Histone acetyltransferase activity of p300 is required for transcriptional repression by the promyelocytic leukemia zinc finger protein. Mol Cell Biol 25 (2005) 5552-5566
11. Wang S., Ai X., Freeman S.D., Pownall M.E., Lu Q., Kessler D.S., and Emerson Jr. C.P. QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signaling in mesoderm induction and angiogenesis. Proc Natl Acad Sci U S A 101 (2004) 4833-4838
12. Li J., Kleeff J., Abiatari I., Kayed H., Giese N.A., Felix K., Giese T., Buchler M.W., and Friess H. Enhanced levels of Hsulf-1 interfere with heparin-binding growth factor signaling in pancreatic cancer. Mol Cancer 4 (2005) 14
13. Kruger J.S., and Reddy K.B. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res 1 (2003) 801-809
14. Mine N., Iwamoto R., and Mekada E. HB-EGF promotes epithelial cell migration in eyelid development. Development 132 (2005) 4317-4326
15. Kim S.H., Ahn S., Han J.W., Lee H.W., Lee H.Y., Lee Y.W., Kim M.R., Kim K.W., Kim W.B., and Hong S. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 315 (2004) 964-970
16. Shridhar V., Sen A., Chien J., Staub J., Avula R., Kovats S., Lee J., Lillie J., and Smith D.I. Identification of underexpressed genes in early- and late-stage primary ovarian tumors by suppression subtraction hybridization. Cancer Res 62 (2002) 262-270
17. Herold C., Ganslmayer M., Ocker M., Hermann M., Geerts A., Hahn E.G., and Schuppan D. The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 36 (2002) 233-240
18. Ogawa K., Yasumura S., Atarashi Y., Minemura M., Miyazaki T., Iwamoto M., Higuchi K., and Watanabe A. Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells. J Hepatol 40 (2004) 278-284
19. Coradini D., and Speranza A. Histone deacetylase inhibitors for treatment of hepatocellular carcinoma. Acta Pharmacol Sin 26 (2005) 1025-1033
20. Ocker M., Alajati A., Ganslmayer M., Zopf S., Luders M., Neureiter D., Hahn E.G., Schuppan D., and Herold C. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol 131 (2005) 385-394
21. Armeanu S., Pathil A., Venturelli S., Mascagni P., Weiss T.S., Gottlicher M., Gregor M., Lauer U.M., and Bitzer M. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol 42 (2005) 210-217
22. Schuchmann M., Schulze-Bergkamen H., Fleischer B., Schattenberg J.M., Siebler J., Weinmann A., Teufel A., Worns M., Fischer T., Strand S., Lohse A.W., and Galle P.R. Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15 (2006) 227-230
23. Datta S.R., Brunet A., and Greenberg M.E. Cellular survival. a play in three Akts. Genes Dev 13 (1999) 2905-2927
24. Clark A.S., West K., Streicher S., and Dennis P.A. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 1 (2002) 707-717
25. Rosato R.R., Almenara J.A., Dai Y., and Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol Cancer Ther 2 (2003) 1273-1284
26. Rosato R.R., Almenara J.A., and Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63 (2003) 3637-3645
27. Maggio S.C., Rosato R.R., Kramer L.B., Dai Y., Rahmani M., Paik D.S., Czarnik A.C., Payne S.G., Spiegel S., and Grant S. The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells. Cancer Res 64 (2004) 2590-2600
28. Romanski A., Bacic B., Bug G., Pfeifer H., Gul H., Remiszewski S., Hoelzer D., Atadja P., Ruthardt M., and Ottmann O.G. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica 89 (2004) 419-426
29. Hague A., Manning A.M., Hanlon K.A., Huschtscha L.I., Hart D., and Paraskeva C. Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway. implications for the possible role of dietary fibre in the prevention of large-bowel cancer. Int J Cancer 55 (1993) 498-505
30. Mandal M., Olson D.J., Sharma T., Vadlamudi R.K., and Kumar R. Butyric acid induces apoptosis by up-regulating Bax expression via stimulation of the c-Jun N-terminal kinase/activation protein-1 pathway in human colon cancer cells. Gastroenterology 120 (2001) 71-78
31. Chen Z., Clark S., Birkeland M., Sung C.M., Lago A., Liu R., Kirkpatrick R., Johanson K., Winkler J.D., and Hu E. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett 188 (2002) 127-140
32. Mandal M., and Kumar R. Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ 7 (1996) 311-318
33. Glaser K.B., Staver M.J., Waring J.F., Stender J., Ulrich R.G., and Davidsen S.K. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors. defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2 (2003) 151-163
34. Marchion D.C., Bicaku E., Daud A.I., Richon V., Sullivan D.M., and Munster P.N. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 92 (2004) 223-237
35. Kim J.S., Lee S., Lee T., Lee Y.W., and Trepel J.B. Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 281 (2001) 866-871
36. Kim J.S., Jeung H.K., Cheong J.W., Maeng H., Lee S.T., Hahn J.S., Ko Y.W., and Min Y.H. Apicidin potentiates the imatinib-induced apoptosis of Bcr-Abl-positive human leukaemia cells by enhancing the activation of mitochondria-dependent caspase cascades. Br J Haematol 124 (2004) 166-178
37. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 40 (2005) 1-13
38. Keen J.C., Yan L., Mack K.M., Pettit C., Smith D., Sharma D., and Davidson N.E. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Res Treat 81 (2003) 177-186